Novavax Net Worth
Novavax Net Worth Breakdown | NVAX |
Novavax Net Worth Analysis
Novavax's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Novavax's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Novavax's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Novavax's net worth analysis. One common approach is to calculate Novavax's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Novavax's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Novavax's net worth. This approach calculates the present value of Novavax's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Novavax's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Novavax's net worth. This involves comparing Novavax's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Novavax's net worth relative to its peers.
Enterprise Value |
|
To determine if Novavax is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Novavax's net worth research are outlined below:
| Novavax generated a negative expected return over the last 90 days | |
| Novavax has high historical volatility and very poor performance | |
| Novavax has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 682.16 M. Net Loss for the year was (187.5 M) with profit before overhead, payroll, taxes, and interest of 112.52 M. | |
| Novavax currently holds about 1.28 B in cash with (87.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Novavax has a poor financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Some Novavax, Inc. Analysts Just Made A Major Cut To Next Years Estimates |
Novavax Quarterly Good Will |
|
Novavax uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Novavax. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Novavax's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Novavax Target Price Consensus
Novavax target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Novavax's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Buy |
Most Novavax analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Novavax stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Novavax, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNovavax Target Price Projection
Novavax's current and average target prices are 7.99 and 16.00, respectively. The current price of Novavax is the price at which Novavax is currently trading. On the other hand, Novavax's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Novavax Target Price
Know Novavax's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Novavax is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novavax backward and forwards among themselves. Novavax's institutional investor refers to the entity that pools money to purchase Novavax's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-12-31 | 1.4 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.4 M | Tsp Capital Management Group/llc | 2024-12-31 | 1.4 M | Sg Americas Securities, Llc | 2024-12-31 | 1.2 M | Citigroup Inc | 2024-12-31 | 1 M | Millennium Management Llc | 2024-12-31 | 1 M | Goldman Sachs Group Inc | 2024-12-31 | 957.7 K | Jane Street Group Llc | 2024-12-31 | 951.9 K | Citadel Advisors Llc | 2024-12-31 | 853.5 K | Vanguard Group Inc | 2024-12-31 | 15.7 M | Blackrock Inc | 2024-12-31 | 13.5 M |
Follow Novavax's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.31 B.Market Cap |
|
Project Novavax's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.14) | |
| Return On Capital Employed | (0.61) | (0.64) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | 0.30 | 0.29 |
When accessing Novavax's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Novavax's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Novavax's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Novavax's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novavax. Check Novavax's Beneish M Score to see the likelihood of Novavax's management manipulating its earnings.
Evaluate Novavax's management efficiency
Novavax has return on total asset (ROA) of (0.0863) % which means that it has lost $0.0863 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.982) %, meaning that it created substantial loss on money invested by shareholders. Novavax's management efficiency ratios could be used to measure how well Novavax manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.14 in 2025. Return On Capital Employed is likely to drop to -0.64 in 2025. At this time, Novavax's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 453 M in 2025, whereas Other Current Assets are likely to drop slightly above 59.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (4.10) | (3.89) | |
| Tangible Book Value Per Share | (4.81) | (4.57) | |
| Enterprise Value Over EBITDA | (8.55) | (8.98) | |
| Price Book Value Ratio | (1.96) | (1.86) | |
| Enterprise Value Multiple | (8.55) | (8.98) | |
| Price Fair Value | (1.96) | (1.86) | |
| Enterprise Value | 831.4 M | 873 M |
Evaluating the management effectiveness of Novavax allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Novavax Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 0.8944 | Revenue | Quarterly Revenue Growth (0.70) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Novavax insiders, such as employees or executives, is commonly permitted as long as it does not rely on Novavax's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Novavax insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Novavax Corporate Filings
F3 | 12th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 27th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
Novavax Earnings Estimation Breakdown
The calculation of Novavax's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Novavax is estimated to be -0.4235 with the future projection ranging from a low of -0.5773 to a high of -0.25. Please be aware that this consensus of annual earnings estimates for Novavax is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.58 Lowest | Expected EPS | -0.25 Highest |
Novavax Earnings Projection Consensus
Suppose the current estimates of Novavax's value are higher than the current market price of the Novavax stock. In this case, investors may conclude that Novavax is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Novavax's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 7 | 40.03% | -0.52 | -0.4235 | -1.23 |
Novavax Earnings per Share Projection vs Actual
Actual Earning per Share of Novavax refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Novavax predict the company's earnings will be in the future. The higher the earnings per share of Novavax, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Novavax Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Novavax, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Novavax should always be considered in relation to other companies to make a more educated investment decision.Novavax Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Novavax's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-26 | 2024-12-31 | -0.5138 | -0.52 | -0.0062 | 1 | ||
2024-11-07 | 2024-09-30 | -0.83 | -0.7579 | 0.0721 | 8 | ||
2024-08-08 | 2024-06-30 | 1.64 | 0.99 | -0.65 | 39 | ||
2024-05-10 | 2024-03-31 | -1.06 | -1.05 | 0.01 | 0 | ||
2024-02-28 | 2023-12-31 | -0.45 | -1.44 | -0.99 | 220 | ||
2023-11-09 | 2023-09-30 | -1.83 | -1.26 | 0.57 | 31 | ||
2023-08-08 | 2023-06-30 | -1.39 | 0.58 | 1.97 | 141 | ||
2023-05-09 | 2023-03-31 | -3.46 | -3.41 | 0.05 | 1 | ||
2023-02-28 | 2022-12-31 | -0.92 | -2.28 | -1.36 | 147 | ||
2022-11-08 | 2022-09-30 | 1.57 | -2.15 | -3.72 | 236 | ||
2022-08-08 | 2022-06-30 | 5.5 | -6.53 | -12.03 | 218 | ||
2022-05-09 | 2022-03-31 | 2.69 | 2.56 | -0.13 | 4 | ||
2022-02-28 | 2021-12-31 | -1.8 | -11.18 | -9.38 | 521 | ||
2021-11-04 | 2021-09-30 | -3.91 | -4.31 | -0.4 | 10 | ||
2021-08-05 | 2021-06-30 | -3.63 | -4.75 | -1.12 | 30 | ||
2021-05-10 | 2021-03-31 | -3.6 | -3.05 | 0.55 | 15 | ||
2021-03-01 | 2020-12-31 | -1.49 | -2.7 | -1.21 | 81 | ||
2020-11-09 | 2020-09-30 | 1.73 | -3.21 | -4.94 | 285 | ||
2020-08-10 | 2020-06-30 | -0.42 | -0.3 | 0.12 | 28 | ||
2020-05-11 | 2020-03-31 | -0.78 | -0.58 | 0.2 | 25 | ||
2020-03-11 | 2019-12-31 | -1.06 | -1.13 | -0.07 | 6 | ||
2019-11-07 | 2019-09-30 | -0.98 | -1.11 | -0.13 | 13 | ||
2019-08-07 | 2019-06-30 | -1.68 | -1.69 | -0.01 | 0 | ||
2019-05-02 | 2019-03-31 | -2.4 | -2.2 | 0.2 | 8 | ||
2019-03-18 | 2018-12-31 | -2.6 | -2.6 | 0.0 | 0 | ||
2018-11-07 | 2018-09-30 | -2.35 | -2.4 | -0.05 | 2 | ||
2018-08-08 | 2018-06-30 | -2.43 | -2.4 | 0.03 | 1 | ||
2018-05-09 | 2018-03-31 | -2.68 | -2.8 | -0.12 | 4 | ||
2018-03-14 | 2017-12-31 | -3.09 | -3.2 | -0.11 | 3 | ||
2017-11-07 | 2017-09-30 | -3.2 | -3.0 | 0.2 | 6 | ||
2017-08-08 | 2017-06-30 | -3.16 | -3.2 | -0.04 | 1 | ||
2017-05-08 | 2017-03-31 | -3.34 | -3.2 | 0.14 | 4 | ||
2017-02-27 | 2016-12-31 | -4.58 | -4.2 | 0.38 | 8 | ||
2016-11-09 | 2016-09-30 | -5.25 | -4.8 | 0.45 | 8 | ||
2016-08-09 | 2016-06-30 | -5.05 | -5.8 | -0.75 | 14 | ||
2016-05-04 | 2016-03-31 | -5.42 | -5.8 | -0.38 | 7 | ||
2016-02-29 | 2015-12-31 | -2.85 | -5.8 | -2.95 | 103 | ||
2015-11-09 | 2015-09-30 | -1.87 | -2.4 | -0.53 | 28 | ||
2015-08-10 | 2015-06-30 | -1.86 | -1.6 | 0.26 | 13 | ||
2015-05-07 | 2015-03-31 | -2.29 | -2.0 | 0.29 | 12 | ||
2015-02-26 | 2014-12-31 | -1.67 | -2.6 | -0.93 | 55 | ||
2014-11-05 | 2014-09-30 | -1.37 | -1.6 | -0.23 | 16 | ||
2014-08-06 | 2014-06-30 | -1.35 | -1.6 | -0.25 | 18 | ||
2014-05-07 | 2014-03-31 | -1.44 | -1.4 | 0.04 | 2 | ||
2014-03-10 | 2013-12-31 | -1.52 | -1.4 | 0.12 | 7 | ||
2013-11-07 | 2013-09-30 | -1.2 | -1.8 | -0.6 | 50 | ||
2013-08-08 | 2013-06-30 | -1.2 | -1.6 | -0.4 | 33 | ||
2013-05-07 | 2013-03-31 | -1.14 | -1.4 | -0.26 | 22 | ||
2013-03-01 | 2012-12-31 | -0.87 | -1.4 | -0.53 | 60 | ||
2012-11-02 | 2012-09-30 | -0.87 | -1.0 | -0.13 | 14 | ||
2012-08-03 | 2012-06-30 | -0.96 | -1.0 | -0.04 | 4 | ||
2012-05-04 | 2012-03-31 | -0.76 | -1.2 | -0.44 | 57 | ||
2012-03-09 | 2011-12-31 | -0.77 | -0.6 | 0.17 | 22 | ||
2011-11-04 | 2011-09-30 | -0.97 | -0.6 | 0.37 | 38 | ||
2011-08-05 | 2011-06-30 | -1.4 | -0.6 | 0.8 | 57 | ||
2011-05-10 | 2011-03-31 | -1.35 | -1.4 | -0.05 | 3 | ||
2011-03-28 | 2010-12-31 | -1.72 | -1.2 | 0.52 | 30 | ||
2010-11-05 | 2010-09-30 | -1.77 | -2.0 | -0.23 | 12 | ||
2010-08-06 | 2010-06-30 | -2.03 | -1.8 | 0.23 | 11 | ||
2010-05-10 | 2010-03-31 | -2.48 | -2.2 | 0.28 | 11 | ||
2010-03-12 | 2009-12-31 | -1.13 | -3.0 | -1.87 | 165 | ||
2009-11-06 | 2009-09-30 | -1.8 | -1.6 | 0.2 | 11 | ||
2009-08-07 | 2009-06-30 | -2.1 | -2.0 | 0.1 | 4 | ||
2009-05-08 | 2009-03-31 | -2.4 | -2.4 | 0.0 | 0 | ||
2009-03-31 | 2008-12-31 | -2.6 | -2.2 | 0.4 | 15 | ||
2008-11-10 | 2008-09-30 | -3 | -3.2 | -0.2 | 6 | ||
2008-08-08 | 2008-06-30 | -2.73 | -2.8 | -0.07 | 2 | ||
2008-05-09 | 2008-03-31 | -2.53 | -2.4 | 0.13 | 5 | ||
2008-03-14 | 2007-12-31 | -2.87 | -3.0 | -0.13 | 4 | ||
2007-11-12 | 2007-09-30 | -2.6 | -3.0 | -0.4 | 15 | ||
2007-08-09 | 2007-06-30 | -2.53 | -2.6 | -0.07 | 2 | ||
2007-05-10 | 2007-03-31 | -2 | -2.8 | -0.8 | 40 | ||
2007-03-14 | 2006-12-31 | -1.87 | -2.0 | -0.13 | 6 | ||
2006-11-14 | 2006-09-30 | -2.13 | -1.6 | 0.53 | 24 | ||
2006-08-14 | 2006-06-30 | -1.47 | -2.0 | -0.53 | 36 | ||
2006-05-15 | 2006-03-31 | -2.7 | -2.2 | 0.5 | 18 | ||
2006-03-01 | 2005-12-31 | -1.6 | 2.6 | 4.2 | 262 | ||
2005-11-08 | 2005-09-30 | -2.2 | -1.2 | 1.0 | 45 | ||
2005-08-09 | 2005-06-30 | -2.9 | -2.8 | 0.1 | 3 | ||
2005-05-10 | 2005-03-31 | -2.9 | -4.4 | -1.5 | 51 | ||
2005-03-14 | 2004-12-31 | -4.6 | -5.2 | -0.6 | 13 | ||
2004-11-03 | 2004-09-30 | -3.8 | -1.4 | 2.4 | 63 | ||
2004-08-09 | 2004-06-30 | -5.4 | -4.4 | 1.0 | 18 | ||
2004-03-10 | 2003-12-31 | -4 | -2.0 | 2.0 | 50 | ||
2003-11-10 | 2003-09-30 | -3.8 | -2.2 | 1.6 | 42 | ||
2003-08-12 | 2003-06-30 | -3.8 | -3.4 | 0.4 | 10 | ||
2003-05-13 | 2003-03-31 | -3.33 | -4.4 | -1.07 | 32 | ||
2003-03-19 | 2002-12-31 | -4.9 | -3.6 | 1.3 | 26 | ||
2002-11-12 | 2002-09-30 | -3.95 | -5.4 | -1.45 | 36 | ||
2002-08-12 | 2002-06-30 | -4.68 | -4.4 | 0.28 | 5 | ||
2002-05-09 | 2002-03-31 | -4 | -4.4 | -0.4 | 10 | ||
2002-02-20 | 2001-12-31 | -2.92 | -2.8 | 0.12 | 4 | ||
2001-11-05 | 2001-09-30 | -1.6 | -2.2 | -0.6 | 37 | ||
2001-08-09 | 2001-06-30 | -1.8 | -1.6 | 0.2 | 11 | ||
2001-05-07 | 2001-03-31 | -1.8 | -2.0 | -0.2 | 11 | ||
2001-03-12 | 2000-12-31 | -3.6 | -5.0 | -1.4 | 38 | ||
2000-11-10 | 2000-09-30 | -2 | -3.4 | -1.4 | 70 | ||
1997-05-02 | 1997-03-31 | -2.4 | -2.2 | 0.2 | 8 | ||
1996-11-14 | 1996-09-30 | -2.6 | -2.0 | 0.6 | 23 |
Novavax Corporate Management
| Mark Casey | Chief VP | Profile | |
| JD Esq | Senior Officer | Profile | |
| Robert MD | Senior Officer | Profile | |
| Ian Watkins | Executive Officer | Profile |
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.